| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.089 | 0.03 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.15 | 0.03 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.03 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.16 | 0.03 |
| mRNA | selumetinib:decitabine (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.03 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.03 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.03 |